Instil Bio, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TIL Nasdaq 2830 instilbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Instil Bio, Inc.

Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco - Jan 6th, 2026 5:00 am
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 13th, 2025 5:00 am
Tumor Infiltrating Lymphocytes Therapy Market Research Report 2025-2030: Market Driven by Active R&D from Iovance Biotherapeutics, Juncell Therapeutics, Biosyngen, and Instil Bio - Oct 21st, 2025 3:34 am
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC) - Sep 10th, 2025 5:00 am
Instil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the company - Aug 16th, 2025 6:23 am
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 13th, 2025 4:00 am
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China - Jul 31st, 2025 4:00 am
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors - Jul 2nd, 2025 4:00 am
Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know - Jun 20th, 2025 10:00 am
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet - Jun 16th, 2025 7:55 am
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program - Jun 11th, 2025 5:00 am
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice - Jun 4th, 2025 10:00 am
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer - Jun 2nd, 2025 5:00 am
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference - May 30th, 2025 5:00 am
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock? - May 29th, 2025 10:00 am
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade - May 29th, 2025 7:55 am
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago - May 23rd, 2025 5:00 am
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025 - May 22nd, 2025 4:00 am
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 13th, 2025 5:00 am
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Mar 4th, 2025 5:09 am